3-脱氮胸腺素A
3-脱氮胸腺素A 性质
| 沸点 | 624.1±65.0 °C(Predicted) |
|---|---|
| 密度 | 1.75 |
| 储存条件 | = -70C |
| 溶解度 | 可溶于 DMSO（高达 20 mg/ml） |
| 形态 | 液体 |
| 酸度系数(pKa) | 13.52±0.70(Predicted) |
| 颜色 | 米色 |
| 水溶解性 | Soluble in Water |
| 稳定性 | 可在-20°C下的DMSO溶液保存长达1个月。 |
3-脱氮胸腺素A 用途与合成方法
EZH2
3-Deazaneplanocin A is a potent histone methyltransferase EZH2 inhibitor. Treatment of OCI-AML3 cells with 3-Deazaneplanocin A (1.0 μM) results in a significant increase in accumulation of cells in the G 0 /G 1 phase (58.5%) with a concomitant decrease in the number of cells in S phase (35.2%) and G 2 /M phases (6.3%) of the cell cycle (P<0.05). Treatment with 3-Deazaneplanocin A (200 nM to 2.0 μM) for 48 hours, dose dependently, inhibits colony growth of OCI-AML3 and HL-60 cells. 3-Deazaneplanocin A reduces the expression of EZH2, especially after 72 hours (e.g. 48%, 32% and 36% reduction of EZH2 in PANC-1, MIA-PaCa-2 and LPc006 cells, respectively). 3-Deazaneplanocin A shows minimal growth inhibition in PANC-1 cells. More than 50% of these cells are still growing after exposure at the highest concentration (20 μM). MIA-PaCa-2 and LPc006 cells are much more sensitive, with IC 0 values of 1±0.3 and 0.1±0.03 μM, respectively. 3-Deazaneplanocin A causes dose-dependent inhibition of cell proliferation of NSCLC cell lines, and the IC 0 values range from 0.08 to 0.24 μM.
The survival of NOD/SCID mice with acute myeloid leukemia (AML) due to HL-60 cells is significantly higher, if treated with 3-Deazaneplanocin A and Panobinostat (PS) compare to treatment with PS, 3-Deazaneplanocin A, or vehicle alone (P<0.05). Median survival is as follows: control, 36 days; PS, 42 days; 3-Deazaneplanocin A, 43 days; and 3-Deazaneplanocin A plus PS, 52 days. There is a progressive increase in weight of rats treated with physiological saline in a time-dependent manner (the mean growth rate=3.19% per day). Administration of 20 mg/kg 3-Deazaneplanocin A not only markedly reduces the relative weight of the rats compare to the initial weight (−2.0%, −4.9% and −1.2%) in the first three days post-treatment, but also suppresses the weight growth rate to 2.6% per day from the fourth day onwards post-dose.
